RNA
Atrium Therapeutics, Inc. Common Stock
NASDAQ: RNA · HEALTHCARE · BIOTECHNOLOGY
$12.99
+3.51% today
Updated 2026-04-29
Market cap
$201.54M
P/E ratio
—
P/S ratio
10.82x
EPS (TTM)
$-4.48
Dividend yield
—
52W range
$12 – $17
Volume
1.5M
WallStSmart proprietary scores
22
out of 100
Grade: F
Strong Sell
Investment rating
5.3
Growth
C+7.3
Quality
B+2.0
Profitability
F6.7
Valuation
B3/9
Piotroski F-Score
Weak
6.3
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →200 stocks currently score above 75
Price targets
Analyst target
$25.00
+92.46%
12-Month target
—
—
Intrinsic (DCF)
$272.98
Margin of safety
+73.29%
Price chart
X-Ray snapshot
Strengths
+ Altman Z 6.31 — safe zone
+ 73.29% below intrinsic value
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at -265.90%
- Negative free cash flow $-20.13M
- Revenue declining -71.10% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $9.22M | $9.56M | $10.90M | $18.62M | $18.62M |
| Net income | $-169.08M | $-212.22M | $-322.30M | $-76.68M | $-29.14M |
| EPS | — | — | — | — | $-4.48 |
| Free cash flow | $-139.09M | $-123.29M | $-307.94M | $-42.57M | $-20.13M |
| Profit margin | -1,833.01% | -2,219.87% | -2,957.71% | -411.88% | -265.90% |
Peer comparison
Smart narrative
Atrium Therapeutics, Inc. Common Stock trades at $12.99. Our Smart Value Score of 22/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 6.31, it sits in the safe zone. TTM revenue stands at $18.62M. with profit margins at -265.90%. Our DCF model estimates intrinsic value at $272.98.
Frequently asked questions
What is Atrium Therapeutics, Inc. Common Stock's stock price?
Atrium Therapeutics, Inc. Common Stock (RNA) trades at $12.99.
Is Atrium Therapeutics, Inc. Common Stock overvalued?
Smart Value Score 22/100 (Grade F, Strong Sell). DCF value $272.98.
What is the price target of Atrium Therapeutics, Inc. Common Stock (RNA)?
The analyst target price is $25.00, representing +92.5% upside from the current price of $12.99.
What is the intrinsic value of Atrium Therapeutics, Inc. Common Stock (RNA)?
Based on our DCF model, intrinsic value is $272.98, a +73.3% margin of safety versus $12.99.
What is Atrium Therapeutics, Inc. Common Stock's revenue?
TTM revenue is $18.62M.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
6.31 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio10.82x
ROE-44.00%
Beta0.93
50D MA$13.85
200D MA$13.85
Shares out0.02B
Float0.02B
Short ratio—
Avg volume1.5M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—